Labisia pumila regulates bone-related genes expressions in postmenopausal osteoporosis model

BMC Complementary and Alternative Medicine

Ahmad Nazrun Shuid¹  Ima Nirwana Soelaiman¹  Isa Naina Mohamed¹  Norliza Muhammad¹  Norazlina Mohamed¹  Siti Noor Fathilah² 

[1] Department of Pharmacology, Faculty of Medicine, The National University of Malaysia (UKM), Jalan Raja Muda Abd Aziz, 50300, Kuala Lumpur, Malaysia;Division of Pharmacology, Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, UPM Serdang, Selangor, Malaysia

关键词: MCSF;    RANKL;    BMP-2;    OPG;    Estrogen;    Postmenopausal osteoporosis;    Labisia pumila;   

Others  :  1221015
DOI  :  10.1186/1472-6882-13-217

 received in 2013-04-02, accepted in 2013-08-30,  发布年份 2013

【 摘 要 】

Background

Labisia Pumila var. alata (LPva) has shown potential as an alternative to estrogen replacement therapy (ERT) in prevention of estrogen-deficient osteoporosis. In earlier studies using postmenopausal model, LPva was able to reverse the ovariectomy-induced changes in biochemical markers, bone calcium, bone histomorphometric parameters and biomechanical strength. The mechanism behind these protective effects is unclear but LPva may have regulated factors that regulate bone remodeling. The aim of this study is to determine the bone-protective mechanism of LPva by measuring the expressions of several factors involved in bone formative and resorptive activities namely Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kappa-B Ligand (RANKL), Macrophage-Colony Stimulating Factor (MCSF) and Bone Morphogenetic Protein-2 (BMP-2).

Methods

Thirty-two female Wistar rats were randomly divided into four groups: Sham-operated (Sham), ovariectomized control (OVXC), ovariectomized with Labisia pumila var. alata (LPva) and ovariectomized with ERT (Premarin®) (ERT). The LPva and ERT were administered via daily oral gavages at doses of 17.5 mg/kg and 64.5 μg/kg, respectively. Following two months of treatment, the rats were euthanized and the gene expressions of BMP-2, OPG, RANKL and MCSF in the femoral bones were measured using a branch - DNA technique.

Results

The RANKL gene expression was increased while the OPG and BMP-2 gene expressions were reduced in the OVXC group compared to the SHAM group. There were no significant changes in the MCSF gene expressions among the groups. Treatment with either LPva or ERT was able to prevent these ovariectomy-induced changes in the gene expressions in ovariectomized rats with similar efficacy.

Conclusion

LPva may protect bone against estrogen deficiency-induced changes by regulating the RANKL, OPG and BMP-2 gene expressions.

【 授权许可】

   
2013 Fathilah et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993, 94:646-650.
• [2]World Health Organization: WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Brussels, Belgium: WHO Press, Geneva; 2007. [Summary Meeting Report] 5–7 May 2004
• [3]Thomsen K, Godfredsen A, Christiansen C: Is Postmenopausal bone loss an age related phenomenon? Calcif Tissue Int 1986, 39:123-127.
• [4]Ismail NMN: Postmenopausal osteoporosis: epidemiology, pathophysiology and treatment. Malaysian J Pathol 1997, 19(1):21-25.
• [5]International Osteoporosis Foundation: Facts and statistics about osteoporosis and its impact. International osteoporosis foundation. J Bone Miner Res 2009, 4:113-118. http://www.iofbonehealth.org/facts-and-statistics.html webcite
• [6]Al-Azzawi F: Prevention of postmenopausal osteoporosis and associated fractures: clinical evaluation of the choice between estrogen and biphosphonates. Gynaecol Endrocrinol 2008, 24:601-609.
• [7]Arcangelo VP, Peterson AM: Pharmacotherapeutics for advanced practice: a practical approach. 2nd edition. USA: Lippincott Williams & Wilkins; 2005.
• [8]Rossouw J, Anderson G, Prentice R: Risks and benefits of estrogen plus progestin in postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002, 288:321-333.
• [9]Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health Initiative randomized trial. JAMA 2003, 289:3243-3253.
• [10]Shumaker SA, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women, the women’s health initiative memory studies: a randomized controlled trial. JAMA 2003, 289:2651-2662.
• [11]Devareddy L, Khalil DA, Smith BJ, Lucas EA, Soung DY, Marlow DD, Arjmandi BH: Soy moderately improves microstructural properties without affecting bone mass in an ovariectomized rat model of osteoporosis. Bone 2006, 8:686-693.
• [12]Devareddy L, Hooshmand S, Collins JK, Lucas EA, Chai SC, Arjmandi BH: Blueberry prevents bone loss in ovariectomized rat model of postmenopausal osteoporosis. J Nutr Biochem 2008, 19:694-699.
• [13]He CC, Hui RR, Tezuka Y, Kadota S, Li JX: Osteoprotective effect of extract from achyranthes bidentata in ovariectomized rats. J Ethnopharmacol 2010, 127:229-234.
• [14]Shuid AN, Zulfadli M, Norliza M, Norazlina M, Ima Nirwana S: Vitamin E exhibit bone anabolic properties. Jour Bone Min Metab 2010, 28:149-156.
• [15]Nazrun AS, Ping LL, Norliza M, Norazlina M, Nirwana SI: The effects of Labisia pumila var.alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. J Ethnopharmacol 2010, 133:538-542.
• [16]Fathilah SN, Ahmad NS, Norazlina M, Norliza M, Nirwana SI: Labisia pumila protects the bone of estrogen-deficient rat model: a histomorphometric study. J Ethnopharmacol 2012, 142:294-299.
• [17]Fathilah SN, Shahrum M, Norazlina M, Ahmad NS: Labisia pumila prevents complications of osteoporosis by increasing bone strength in a rat model of postmenopausal osteoporosis. eCAM 2012., (2012) doi:10.1155/2012/948080.
• [18]Stone BC: Notes on the genus Labisia Lindl. (Myrsinaceae). Malay Nat J 1998, 42:43-51.
• [19]Burkill IH: Dictionary of the Economic Products of the Malay Peninsula. London: Publisher Crown Agents for the Colonies; 1935.
• [20]Runi SP, et al.: Studies on medicinal plant in Sarawak. In Towards Bridging Science and Herbal Industry. Edited by Chang YS. Kuala Lumpur: Forest Research Institute of Malaysia (FRIM); 2001:112-119.
• [21]Zakaria M, Mohammed MA: Traditional Malay Medicinal Plants. Kuala Lumpur: Fajar Bakti; 1994.
• [22]Jamia AJ, Houghton JP, Milligan RS, Jantan I: The oestrogenic and cyto- toxic effects of the extracts of Labisia pumila var. alata and Labisia pumila var. pumila in vitro. Jurnal Sains Kesihatan 2003, 1:53-60.
• [23]Husniza H: Estrogenic and Androgenic Activities of Kacip Fatimah (Labisia pumila). Kuala Lumpur: Abstracts of Research Projects, Institute of Medical Research, Ministry of Health Malaysia; 2002:8.
• [24]Fazliana M, Wan Nazaimoon WM, Gua HF, Östensona CG: Labisia pumila extract regulates body weight and adipokines in ovariectomized rats. Maturitas 2009, 62:91-97.
• [25]Jamia AJ, Houghton JP, Milligan RS: Testing of Labisia pumila for oestro- genic properties using a recombinant yeast screen. J Pharm Pharmacol 1998, 50:79.
• [26]Ayida AW, Wan Nazaimoon WM, Farihah HS, Azian AL: Effect of ovariectomy, Labisia Pumila var. alata treatment and estrogen replacement therapy on the morphology of adipose tissue in ovariectomized Sprague Dawley rats. J Med Biol Sc 2007, 1:1-7.
• [27]Teiteilbaum SL: Bone resorption by osteoclast. Science 2000, 289:1504-1508.
• [28]Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Elliott R, Colombero A, Elliott G, et al.: Osteoprotogerin ligand is a cytokine that regulated osteocast differentiation and activation. Cell 1998, 93:165-176.
• [29]Lewiecki EM: RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006, 6:1041-1050.
• [30]Lloyd SAJ, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, et al.: Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tiss Int 2008, 82(5):361-372.
• [31]Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR: Bone morphogenetic protein-2 biology and applications. Clin Orthop Rel Res 1996, 324:39-46.
• [32]Bord S, Ireland DC, Beavan SR, Compston JE: The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003, 32(2):136-141.
• [33]Siti Noor Fathilah AA: Branched DNA: a novel technique in molecular diagnostics. RUMeS 2013, 1(1):27-29.
• [34]Boyle WJ, Simonest WS, Lacey DL: Osteoclast differentiation and activation. J Nat 2003, 423:337-342.
• [35]Andras SC, Power JB, Cockin EC, Davey MR: Strategies for signal amplification in nucleic acid detection. Mol Biotechnol 2001, 19(1):29-44.
• [36]Ferguson N: Osteoporosis in Focus. Oxford: Pharmaceutical Press; 2004.
• [37]Wan Ezumi MF, Siti Amrah S, Suhaimi AWM, Mohsin SSJ: Evaluation of the female reproductive toxicity of aqueous extracts of Labisia pumila var. alata in rats. Indian J Pharmacol 2007, 39:30-32.
• [38]Singh GD, Ganjoo M, Youssouf MS, Koul A, Sharma R, Singh S, Sangwan PL, Koul S, Ahamad DB, Johri RK: Sub-acute toxicity evaluation of an aqueous extract of Labisia pumila, a Malaysian herb. Food Chem Toxicol 2009, 47:2661-2665.
• [39]Arron JR, Choi Y: Bone versus immune system. Nature 2000, 408:535-536.
• [40]Lorenzo J: Interactions between immune and bone cells: new insights with many are remaining questions. JCI 2000, 106:749-752.
• [41]Choi HK, Kim DH, Kim JW, Ngadiran S, Sarmidi MR, Park CS: Labisia pumila extract protects skin cells from photoaging caused by UVB irradiation. J Biosc Bioeng 2010, 109:291-296.
• [42]Fabien W, Laurent L, Veronique C, Jerome G, Yohann W: Oxidative stress bone remodelling and disease. Trends Mol Med 2009, 15(10):468-475.
• [43]Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O’Brien CA, Bellido T, Parfitt AM, Manolagas SC: Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007, 282:27285-27297.
• [44]Huang J, Zhang H, Shimizu N, Takeda T: Triterpenoid saponins from Arsidia mamillata. Phytochemistry 2000, 54:817-822.
• [45]Norhaiza M, Maziah M, Hakiman M: Antioxidative properties of leaf extracts of a popular Malaysian herb, Labisia pumila. J Med Plants Res 2009, 3:217-223.
• [46]Sies H, Stahl W: Vitamin E and C, beta carotene and other carotenoids as antioxidants. Am J Clin Nutr 1995, 62:1315S-1321S.
• [47]Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinol 1999, 140:4367-4370.
• [48]Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. JCI 2000, 106:1229-1237.
• [49]Jilka RL: Cytokines, bone remodeling, and estrogen deficiency. Bone 1998, 23:75-81.
• [50]Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998, 128:127-137.
• [51]Fuller K, Wong B, Choi Y, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption. J Exp Med 1998, 188:997-1001.
• [52]Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, Ma Y, Yang W, Crawford KL, McMaster GK, Witney F, Luo Y: A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem 2006, 352(1):50-60.
• [53]Chen XW, Garner SC, Anderson JJ: Isoflavones regulate interleukin-6 and osteoprotegerin synthesis osteoblast cell differentiation via an estrogen-receptor dependent pathway. Biochem Biophys Res Commun 2002, 295:417-422.
• [54]Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC: Phytoestrogen genistein stimulates the production of osteoprotegerin by the human trabecular osteoblasts. J Cell Biochem 2002, 84:725-735.
• [55]Yamagishi T, Otsuka E, Hagiwara H: Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinol 2001, 142:3632-3637.
• [56]Kanzaki H, Hatayama H, Narukawa S, Kariya M, Fujita J, Mori T: Hormonal regulation in the production of macrophage colony-stimulating factor and transforming growth factor-beta by human endometrial stromal cells in culture. Horm Res 1995, 44(S2):30-35.
• [57]Zhou S, Turgeman G, Harris SE, Leitman DC, Komm BS, Bodine PV, Gazit D: Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol Endocrinol 2003, 17(1):56-66. doi:10.1210/me.2002-0210.
• [58]Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O’Malley BW, Haussler MR: Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-84.
• [59]Ernst M, Heath JK, Rodan GA: Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinol 1989, 125:825-833.
• [60]Takano-Yamamoto T, Rodan GA: Direct effects of 17b-estradiol on trabecular bone in ovariectomized rats. PNAS 1990, 87:2172-2176.
• [61]Chow JWM, Lean JM, Chambers TJ: 17b-Estradiol stimulates cancellous bone formation in female rats. Endocrinol 1992, 130:3025-3032.